Neurent Medical is dedicated to developing highly innovative non-surgical interventions that treat chronic inflammatory Sino-Nasal diseases. The privately held, venture backed company is based in Galway Ireland. Neurent Medical was founded by CEO Brian Shields and CTO David Townley, culminating from their work at the BioInnovate Ireland program at the National University, Galway.

Leadership Team and Board of Directors

Brian Shields
Co-founder & CEO
Board Member

View Bio

Brian Shields

Brian Shields is the co-founder and CEO of Neurent Medical. Brian spent almost a decade working as a management consultant much of this time spent on the design and commercial rollout of connected health clinical programmes in public and private European health systems and “around the pill” services for the pharmaceutical industry. Brian and David founded Neurent Medical, raising their first capital in 2017. Brian has a PhD in Applied Computing and an MBA.

David Townley
Co-founder & CTO
Board Member

View Bio

David Townley

David Townley is the co-founder and CTO of Neurent Medical. David has extensive experience in the medical device sector with more than 18 years in research and development. He has held senior positions in R&D, technical operations and as a technology consultant in Ireland, USA and Australia. He has authored circa 50 patents (granted/pending) and led multiple medical devices from concept to market in the cardiovascular, ophthalmology, orthopaedic and Endo-surgery fields. David earned a B.Eng in Mechanical Engineering and a Master’s in Quality and Technology Management.

Declan Daly
Chief Financial Officer

View Bio

Declan Daly

Declan is the CFO of Neurent Medical. Declan has significant senior executive experience in the medical device, biotechnology and healthcare sectors in the US and Ireland. Previously Declan has served as the CFO of INAMED Corporation (NASDAQ: IMDC) and Fibrocell Science, Inc. (NYSE MKT: FCSC) where he raised in excess of US$250 million in financing and managed a US$3.2 billion M&A transaction. Mr. Daly began his career in PricewaterhouseCoopers in Dublin and subsequently worked in PricewaterhouseCoopers in London and BDO in Dublin.
Declan is a Fellow of Chartered Accountants Ireland. He has a B.A. (Moderatorship) degree in Management Science & Information System Studies from Trinity College, Dublin and a Professional Diploma in Accounting from Dublin City University.

Karen Peterson
VP of Clinical, Regulatory & Quality

View Bio

Karen Peterson

Karen is responsible for clinical, regulatory, and quality at Neurent Medical. Karen has significant executive leadership experience in the medical device industry in the areas of clinical, regulatory, and quality for both large and start-up companies, including ten years in the ENT space. She has a successful track record in designing and running clinical studies, obtaining positive clinical study outcomes, obtaining numerous FDA and worldwide regulatory approvals, and ensuring successful QMS audits. Karen holds a Master of Science degree in Biometry and Health Information Systems from the University of Minnesota, and a Bachelor of Science degree from the University of Wisconsin.

Brent Shreiner
VP Sales

View Bio

Brent Shreiner

Brent leads sales at Neurent Medical. He has extensive experience in sales leadership serving the ENT industry and has been integral to the success of several medical device startups, supporting first-in-class procedures and products. He has built and managed high-performing sales teams in the fast-growing ENT office channel and has worked in various healthcare spaces, including cardiology/cardiothoracic surgery, radiology, neuro and endovascular. He also has experience in healthcare information technology, capital equipment sales and sales leadership. Brent is a graduate of DePauw University.

Mark Fletcher
Chairman of the Board
Former President, Medtronic Surgical Technologies

View Bio

Mark Fletcher

Mark Fletcher is the former President and CEO of Katena Products, a leading ophthalmic surgical instrumentation company. Prior to Katena, Mark was President of the Surgical Technologies business of Medtronic. During his 7 year tenure, Mark successfully achieved significant growth of Medtronic PLC’s $2 billion surgical technologies division through disruptive innovation, aggressive expansion, and strategic M&A. Mark was also President of Medtronic ENT, providing ear, nose and throat treatment technologies, and Vice-President/General Manager and Founder of Solan Ophthalmology and VP of Xomed Surgical Products, a leader in sinus surgical instrumentation, both of which were acquired by Medtronic in 1999 for over $800 million. He is also a board member of several start-up medical technology companies worldwide, and co-founder of Shruthi, an organization dedicated to bringing ear health to the underserved in India.

Justin Lynch
Board Member
Partner & CFO,
Fountain Healthcare Partners

View Bio

Justin Lynch

Justin Lynch is a partner in Fountain Healthcare Partners and also serves as the CFO of the firm. He joined the team prior to the launch of Fund I in 2008. Justin has a BA in Accounting and Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over 25 years of experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science. Justin has a particular interest in the medical device sector and led the firm’s investments in Neurent Medical, Vivasure Medical, Neuravi (exited to J&J) and Medical Microinstruments.

Eamon Brady
Board Member
CEO,
WhiteSwell

View Bio

Eamon Brady

Eamon Brady has over 25 years MedTech experience and is the CEO of WhiteSwell, a science-driven company dedicated to improving treatment of acute decompensated heart failure (ADHF). Prior to WhiteSwell, Eamon was the founder and CEO of Neuravi a stroke interventional company that exited to JNJ in April 2017. Prior to Neuravi Eamon led international teams as both Global Director of R&D and Director of New Ventures at Abbott Vascular. He was a member of the founding team of MedNova Ltd., a company that pioneered embolic protection for carotid stenting, and helped lead the company to an acquisition by Abbott Vascular. Eamon has an engineering background and is a prolific inventor with over 200 US patents, granted or pending. He has a keen interest in all aspects of strategy, building teams and technology, innovation and patient care.

Drew Burdon
Board Member
LSP

View Bio

Drew Burdon

Drew Burdon, PhD, MBA, joined LSP in 2019 as an Investment Manager. Drew’s primary responsibility within LSP is to invest in private companies, and Drew has a specific focus on the health economics funds, targeting Med Tech, Digital and Diagnostic investment opportunities. Drew has been involved in many investment opportunities during his LSP career and he led the investments in One Projects (Ireland) and Neurent Medical (Ireland). Drew holds Board Director positions for both of these companies.

Prior to joining LSP, Drew had a 13-year career at Smith & Nephew, performing in a range of increasingly senior roles across a number of functional areas including R&D, commercial strategy, marketing (including product launch) and business development. Immediately prior to joining LSP, Drew was a Director of Corporate Development with Smith & Nephew, where Drew developed and transacted share and asset acquisitions, divestments and made equity investments on behalf of the company. Of particular note, Drew led the acquisitions of Rotation Medical (US) and Ceterix Orthopaedics (US). Additionally, Drew led equity investments in Trice Medical (US) and Leaf Healthcare (US) and held Board observer positions with Leaf Healthcare (US) and OrthoSpace (Israel).

Gerry Maguire
General Partner
Atlantic Bridge

View Bio

Gerry Maguire

Gerry is a General Partner at Atlantic Bridge and is an experienced Investor, Executive and Design Engineer with a thirty-year career in the technology industry.

Prior to joining Atlantic Bridge, he was Vice President R&D at Parthus Technologies responsible for managing a business which included divisions in Ireland, UK and USA. Gerry joined the company in 1993 and played a key role in its transition from startup to successful IPO on Nasdaq. Gerry also held senior management roles at several technology companies including Philips and Texas Instruments.
Gerry has a BA, BAI degree in Electronic Engineering from Trinity College Dublin and a Diploma in Company Direction from the Institute of Directors.

SOME OF OUR

New Data show NEUROMARK^® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

21st March 2023

Significant Symptom Improvements

Neurent Medical Announces Limited Market Release of NEUROMARK^® System to Treat Chronic Rhinitis

3rd February 2023

Press release about Limited Release

Neurent Medical Receives FDA Clearance for NEUROMARK^™, a Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis

18th November 2021

Press release about FDA Clearance

View Older Press Releases

About Us

New Data show NEUROMARK® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

21st March 2023

Neurent Medical Announces Limited Market Release of NEUROMARK® System to Treat Chronic Rhinitis

3rd February 2023

Neurent Medical Receives FDA Clearance for NEUROMARK™, a Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis

18th November 2021

General Enquiries

If you are a HealthCare Professional: Contact Customer Service to Place an Order

New Data show NEUROMARK^® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

Neurent Medical Announces Limited Market Release of NEUROMARK^® System to Treat Chronic Rhinitis

Neurent Medical Receives FDA Clearance for NEUROMARK^™, a Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis